Efficacy of total glucosides of paeonia in patients with stable chronic heart failure and its effect on inflammation
-
摘要: 目的:探讨白芍总苷 (TGP) 治疗稳定期慢性心力衰竭 (CHF) 患者的效果及其对炎症水平的影响。方法:选取2015-07-01-2017-01-31我院收治的168例CHF患者为研究对象, 随机分为试验组82例和对照组86例。对照组给予常规门诊复查和心力衰竭 (心衰) 药物治疗, 试验组在对照组的基础上给予TGP治疗。所有入选者在纳入研究时和之后3个月采集空腹静脉血, 检测其肿瘤坏死因子-α (TNF-α)、白细胞介素-6 (IL-6) 和半乳糖凝集素-3 (G-3), 同时记录出院后12个月的再入院情况、B型脑钠肽 (BNP)、左室射血分数 (LVEF) 及试验组的不良反应情况。结果:治疗后试验组患者TNF-α、IL-6和G-3水平均显著低于对照组。出院后12个月试验组的再住院率和BNP水平均显著低于对照组, 而LVEF水平显著升高。试验组中3例 (3.7%) 患者出现软便及大便次数增多, 但无需停药。结论:TGP可改善CHF患者体内炎症水平、降低住院率、改善心衰指标, 并且其不良反应较少, 值得在临床工作中进一步应用。Abstract: Objective: To explore the efficacy of total glucosides of paeonia (TGP) in patients with stable chronic heart failure (CHF) and its effect on inflammation.Method: This study included 168 CHF patients who were admitted to our hospital between 2015-07-01-2017-01-31, and were randomly divided into the test group (82 cases) and the control group (86 cases).The control group was given routine outpatient follow-up and conventional heart failure drugs, and the test group was given TGP on the basis of the control group.Abdominal venous blood were evacuated from all participants to detect tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and galectin-3 (G-3) at the time of enrollment and 3 months after enrollment, and readmission.Brain natriuretic peptide (BNP), left ventricular ejection fraction (LVEF) and adverse reactions were recorded simultaneously.Result: The levels of TNF-α, IL-6, and G-3 in the test group were significantly lower than those in the control group after treatment.Compared with the control group, the trial group had a lower readmission rate and BNP level and a higher LVEF at 1 year after discharge.3 cases (3.7%) in the test group developed soft stools and increased stool frequency without stopping TGP.Conclusion: TGP can decrease the level of inflammation and improve heart failure indicators in patients with chronic heart failure and reduce the readmission rate with fewer adverse reactions.It is worth further applying in clinical work.
-
Key words:
- total glucosides of paeonia /
- chronic heart failure /
- inflammation /
- prognosis
-
-
[1] 周云艳, 孔一慧, 李为民.心力衰竭与炎性细胞因子相关研究新进展[J].心血管病学进展, 2014, 35 (5):543-546.
[2] Kalogeropoulos A, Georgiopoulou V, Psaty BM, et al.Inflammatory markers and incident heart failure risk in older adults:the Health ABC (Health, Aging, and Body Composition) study[J].J Am Coll Cardiol, 2010, 55 (19):2129-2137.
[3] 全振华, 刘莉, 艾民, 等.中药抑制炎症标志物干预慢性心力衰竭的研究进展[J].国际检验医学杂志, 2016, 37 (8):1092-1094.
[4] 王小艳, 陈星宇, 张洪英.白芍总苷在皮肤科中的应用进展[J].中国中西医结合皮肤性病学杂志, 2015, 14 (4):262-264.
[5] 蒋旭宏, 华军益, 潘智敏, 等.白芍总苷对内毒素性心肌炎大鼠心肌组织炎性因子的影响[J].浙江医学, 2014, 36 (3):182-183, 186.
[6] 王晓纲.白芍总苷对动脉粥样硬化大鼠氧化应激和炎症反应的抑制作用[J].实用药物与临床, 2017, 20 (2):140-143.
[7] 韩蕾, 周晓辉, 王雄伟, 等.白芍总苷对腹主动脉结扎所致大鼠心肌重构的影响[J].中华中医药学刊, 2011, 29 (2):330-334.
[8] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志, 2014, 42 (2):98-122.
[9] 闵伟琪, 魏琴, 李洪毓, 等.白芍总苷治疗类风湿关节炎的多中心临床研究[J].中华风湿病学杂志, 2005, 9 (8):487-491.
[10] 齐向明, 朱启金, 吴永贵.白芍总苷对2型糖尿病肾脏疾病患者外周血炎症介质的影响[J].临床肾脏病杂志, 2015, 15 (11):650-654.
[11] 陈文莉, 邹卫, 徐力, 等.白芍总苷对维持性腹膜透析患者微炎症状态的影响[J].临床肾脏病杂志, 2016, 16 (3):148-151.
[12] Wu AH, Wians F, Jaffe A.Biological variation of galectin-3and soluble ST2 for chronic heart failure:implication on interpretation of test results[J].Am Heart J, 2013, 165 (6):995-999.
[13] Lok DJ, Van Der Meer P, de la Porte PW, et al.Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure:data from the DEAL-HF study[J].Clin Res Cardiol, 2010, 99 (5):323-328.
[14] 王红权, 詹杰.白芍总苷治疗类风湿关节炎药理作用及机制[J].医药导报, 2015, 34 (2):199-201.
[15] 杜旭召, 杨豪, 邓素玲, 等.白芍总苷对骨关节炎软骨细胞增殖及分泌表达的影响[J].中国骨质疏松杂志, 2016, 22 (11):1375-1379, 1385.
[16] 岳利环, 林进, 徐立勤, 等.甲氨蝶呤联合白芍总苷治疗幼年特发性关节炎临床观察[J].风湿病与关节炎, 2017, 6 (1):18-21.
[17] 毛红群, 栾超, 宗文凯, 等.白芍总苷联合左西替利嗪及他克莫司软膏治疗严重面部激素依赖性皮炎的疗效和安全性评价[J].中华皮肤科杂志, 2014, 47 (12):891-893.
[18] 蔡茵萍, 祝亚文, 张爱军.芪苈强心胶囊对慢性心力衰竭患者血清半乳糖凝集素-3的影响[J].中西医结合心脑血管病杂志, 2013, 11 (7):801-802.
-
计量
- 文章访问数: 364
- PDF下载数: 111
- 施引文献: 0
下载: